Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.
Stéphanie Lheureux, MD, PhD
Advertisement
Stéphanie Lheureux, MD, PhD, is a clinician investigator in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre.
Articles by Stéphanie Lheureux, MD, PhD
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.
Advertisement
Latest Updated Articles
Dr Lheureux on Advancements in Targeted Treatment Delivery for Ovarian CancerPublished: February 25th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
3
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
4
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
5